Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies-Reference-Cited by-同舟云学术

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies

Published:2014-01-04 Issue:3 Volume:73 Page:467-473
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Mahadevan Daruka,Sutton Gregory Ryan,Arteta-Bulos Rafael,Bowden Chris J.,Miller Paul J. E.,Swart Rachel Elizabeth,Walker Mark S.,Haluska Paul,Munster Pamela N.,Marshall John,Hamid Omid,Kurzrock Razelle

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-013-2372-x.pdf

Reference27 articles.

1. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4(7):505–518

2. Baserga R (2005) The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 9(4):753–768

3. Kurmasheva RT, Houghton PJ (2006) IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta 1766(1):1–22

4. Sachdev D, Yee D (2007) Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 6(1):1–12

5. Tao Y, Pinzi V, Bourhis J, Deutsch E (2007) Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway–therapeutic perspectives in cancer. Nat Clin Pract Oncol 4(10):591–602

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment;The Journal of Clinical Endocrinology & Metabolism;2024-06-15

2. The Adverse Effects Profile of Teprotumumab;The Journal of Clinical Endocrinology & Metabolism;2023-04-18

3. Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy;Ophthalmic Plastic & Reconstructive Surgery;2023-03-03

4. The Therapeutic Landscape of Salivary Gland Malignancies—Where Are We Now?;International Journal of Molecular Sciences;2022-11-28

5. Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease;The Journal of Clinical Endocrinology & Metabolism;2022-08-08